Radiant energy – Supported for nonsignalling objects of irradiation – With source support
Reexamination Certificate
2005-09-27
2005-09-27
Berman, Jack I. (Department: 2881)
Radiant energy
Supported for nonsignalling objects of irradiation
With source support
C250S50400H, C250S492100
Reexamination Certificate
active
06949753
ABSTRACT:
Methods and compositions are described for treating contaminants in material intended for in vivo use, and in particular blood and blood products for human use. Contaminants in blood cell preparations are inactivated prior to long term storage and transfusion. Inactivation is accomplished using a device having a unique temperature control design.
REFERENCES:
patent: 1961700 (1934-06-01), Moehler
patent: 2056614 (1936-10-01), Moehler
patent: 2169081 (1939-04-01), James
patent: 2212330 (1940-08-01), Thomas
patent: 3776694 (1973-12-01), Leittl
patent: 3852032 (1974-12-01), Urbach
patent: 4124598 (1978-11-01), Hearst et al.
patent: 4169204 (1979-09-01), Hearst et al.
patent: 4196281 (1980-04-01), Hearst et al.
patent: 4250390 (1981-02-01), Nicholson
patent: 4312883 (1982-01-01), Baccichetti et al.
patent: 4321919 (1982-03-01), Edelson
patent: 4398031 (1983-08-01), Bender et al.
patent: 4421987 (1983-12-01), Herold
patent: 4535247 (1985-08-01), Kurtz
patent: 4545987 (1985-10-01), Giles
patent: 4573962 (1986-03-01), Troutner
patent: 4612007 (1986-09-01), Edelson
patent: 4613322 (1986-09-01), Edelson
patent: 4621195 (1986-11-01), Larsson
patent: 4642171 (1987-02-01), Sekine et al.
patent: 4645649 (1987-02-01), Nagao
patent: 4684521 (1987-08-01), Edelson
patent: 4692138 (1987-09-01), Troutner et al.
patent: 4693981 (1987-09-01), Wiesehahn
patent: 4726949 (1988-02-01), Miripol
patent: 4727027 (1988-02-01), Wiesehahn et al.
patent: 4748120 (1988-05-01), Wiesehahn
patent: 4769131 (1988-09-01), Noll et al.
patent: 4866282 (1989-09-01), Miripol
patent: 4878891 (1989-11-01), Judy
patent: 4915683 (1990-04-01), Sieber
patent: 4952812 (1990-08-01), Miripol et al.
patent: 4960408 (1990-10-01), Klainer et al.
patent: 5030200 (1991-07-01), Judy et al.
patent: 5041078 (1991-08-01), Matthews et al.
patent: 5114670 (1992-05-01), Duffey
patent: 5120649 (1992-06-01), Horowitz et al.
patent: 5133932 (1992-07-01), Gunn et al.
patent: 5166528 (1992-11-01), Le Vay
patent: 5184020 (1993-02-01), Hearst
patent: 5185532 (1993-02-01), Zabsky et al.
patent: 5216251 (1993-06-01), Matschke
patent: 5229081 (1993-07-01), Suda
patent: 5288605 (1994-02-01), Lin
patent: 5288647 (1994-02-01), Zimlich, Jr. et al.
patent: 5304113 (1994-04-01), Sieber et al.
patent: 5342752 (1994-08-01), Platz et al.
patent: 5372929 (1994-12-01), Cimino
patent: 5399719 (1995-03-01), Wollowitz et al.
patent: 5418130 (1995-05-01), Platz
patent: 5459030 (1995-10-01), Lin
patent: 5459322 (1995-10-01), Warkentin
patent: 5503721 (1996-04-01), Hearst et al.
patent: 5593823 (1997-01-01), Wollowitz et al.
patent: 5652096 (1997-07-01), Cimino et al.
patent: 5762867 (1998-06-01), D'Silva
patent: 6433343 (2002-08-01), Cimino et al.
patent: WO 90/07952 (1990-07-01), None
patent: WO 91/03933 (1991-04-01), None
patent: WO 91/06843 (1991-05-01), None
patent: WO 92/11060 (1992-07-01), None
patent: WO 93/17553 (1993-09-01), None
patent: WO 94/03054 (1994-02-01), None
Albarella et al. “Monoadduct forming photochemical reagents for labeling nucleic acids for hybridization”, Nuc. Acids Res. 17:4293-4308.
Alter et al. “Photochemical Decontamination of Blood Components Containing Hepatitis B and Non-A, Non-B Virus,” The Lancet (ii:1446-1450) (1988).
Artuc, M., et al. “Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro” 101:669-677 (1979).
Belogurov and Zavil'gel'skii “Mechanism of the inactivation of the photosensitizer 8-Methoxypsoralen on bacteria and bacteriophages” Sovgenet 14:219-223 (1978).
Bender D. et al., “Psoralen synthesis improvements in furano ring formation application to the synthesis of 4,5′8-trimethylpsoralen,” J. Org. Chem. 44:13 2176-2180 (1979).
Bordin, F. et al. “5′Methylangelicin: a new highly photosensitizing angular furocoumarin” Experientia 35:1567 (1979).
Bridges, B.A. “8-methoxypsoralen and radiation damage in bacteria” Int'l. J. Rad. Bio. 20:185 (date not available).
Buchholz, D.H. et al. “Bacterial proliferation in platelet products stored at room temperature” New Eng. J. of Med. 285:429-433 (1971).
Buchholz, D.H. et al. “Detection and quantitation of bacteria in platelet products stored at ambient temperature” Transfusion 13:268-285 (1973).
Caffieri, S. et al. “Photocycloaddition of 4,5′-Dimethylangelicin to cytosine in the photoreaction with DNA: Isolationof the adduct” Medecine Bio. Envir. 11:386 (1983).
Carmen, R. “The selection of plastic materials for blood bags” Transfusion Med. Rev. 7:1 (1993).
Cimino et al. “Psoralens as Photoactive Probes of Nucleic Acid Structure and Function: Organic Chemistry, Photochemistry, and Biochemistry,” Ann. Rev. Biochem. 54:1151-1193 (1985).
Cimino, G. et al. “Wavelength dependence for the photoreversal of a psoralen-DNA cross-link” Biochem. 25:3013 (1986).
Dall'Acqua et al. “Structure activity studies on the dark and photochemical interaction between methylangelicins and DNA” Medecine Biol. Envir. 9:303 (1981).
Dall'Acqua et al. “Monofunctional 3,4- and 4′5′-Photocycloadducts between 4, 5′-dimethylangelicin and thymine” Photochem. Photobio. 37:373 (1983).
Dall'Acqua et al. “New monofunctional reagents for DNA as possible agents for the photchemotherapy of psoriasis” Deriviatives of 4,5′dimethylangelicin J. Med. Chem 24:178 (1984).
Dodd et al. “Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralen-ultraviolet A and merocyanine 540 visible light methods,” Transfusion 31:483-490 (1991).
Dodd, R. Y. “Will blood products be free of infectious agents?” Nance S.J. ed.Transfusion Med. in the 1990'sAABB (1990).
Ericson and Wollenzien “Use of reverse transcription to determine the exact locations of psoralen photochemical crosslinks in RNA” Analytical Biochem. 174:215-223 (1988).
Friedman L and Stromberg R. “Viral inactivation and reduction in cellular blood products,” Rev. Fr. Transfus. Hemobiol. 36:83-91 (1993).
Goldenberg et al. “Synthesis and Properties of Novel Psoralen Derivatives,” Biochemistry 27:6971-6976 (1988).
Grana et al. “Use of 8-methoxypsoralen and ultraviolet-A pretreated concentrates to prevent Iloimmunization against class I major histocompatibility antigens” Blood 77:2530 (1991).
Groene S. and Shaw D. :Psoralen preparation of antigenically intact noninfectious rotavirus particles, J. Virol. Methods 38 93-102 (1992).
Grossman, B.J. et al. “Screening blood donors for gastrointestinal illness: a strategy to eliminate carriers foYersinia enterocoliticia” Transfusion 31:500 (1991).
Guiotto, G. et al. “Synthesis of some photosensitizingt methylangeiicins, as monofunctional reagents for DNA” Eur. J. Med. Chem-Shim Ther. 16:489 (1981).
Guiotto et al. “6-methylangelicins: A new series of potential photochemotherapeutic agents for the treatment of psoriasis” J. Med. Chem. 27:959-967.
Hanson, C.V. “Photochemical Inactivation of Viruses with Psoralens: An Overview,” Blood Cells: 18:7-25 (1992).
Hass and Webb “8-methoxypsoralen effect on survival and repair of escherichia coli after ultraviolet irradiation: action spectra” Radiation Res. 80:170 (1979).
Heal, J.M. et al. “Fatal salmonella septicemia after platelet transfusion” Transfusion 27:2 (1987).
Hearst et al. “The Reaction of the Psoralens with Deoxyribonucleic Acid,” Quart. Rev. Biophys. 17:1-44 (1984).
Hearst, J.E., and Thiry, L., “The photoinactivation of an RNA animal virus, vesicular stomatitis virus, with the aid of newly synthesized psoralen derivatives,” Nucleic Acids Research, 4:1339-1347 (1977).
Heindel et al. “Aminomethyl psoralens. Elctrophillic substitution of hydroxymethylphthalimide on linear furocoumarins”, J. Hetero. Chem. 22:73-76 (19
Cimino George D.
Simms Romilly John
Berman Jack I.
Cerus Corporation
LandOfFree
Device and method for photoactivation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device and method for photoactivation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device and method for photoactivation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3406245